Skip to content

The impact of pulmonary rehabilitation and self-management support on asthma control in obese patients with asthma

The impact of pulmonary rehabilitation and self-management support on asthma control in obese patients with asthma - Pulmonary rehabilitation and self-management in obese patients with asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40249
Enrollment
36
Registered
2013-11-27
Start date
2014-02-07
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesitas Asthmatic bronchitis overweight

Interventions

- Pulmonary rehabilitation (PRH): during 12 weeks three times a week a training of 60 minutes under supervision of a physiotherapist, and with counselling of a psychologist and a dietician. - Inter

Sponsors

Sint Franciscus Gasthuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Age > 18 and 30 ,and = 0.75 despite optimized medication use (LABA and ICS) -Ability to perform a reproducible lung function test -Ability to use the internet-based self management tool -Ability to participate in pulmonary rehabilitation -Consent to 3, 6 and 12 months follow-up visits. -Patient motivation to achieve the fullest benefit from pulmonary rehabilitation. -Informed consent

Exclusion criteria

Exclusion criteria: -Significant orthopaedic or neurologic problems that reduce mobility or cooperation with physical training -COPD or other pulmonary pathology apart from asthma, except for adequate treated OSAS with a AHI 10 PY in history -Participation in Pulmonary rehabilitation program in last 2 year before the study.

Design outcomes

Primary

MeasureTime frame
Asthma symptom score (asthma control questionnaire (ACQ) score) 3 months after pulmonary rehabilitation.

Secondary

MeasureTime frame
Secondary endpoints will be BMI, asthma quality of life (AQLQ), activity level (move-monitor), exercise capacity (6MWD), lung function (FEV1) and airway inflammation (eosinophils and neutrophils in blood and sputum). Tertiary endpoints will be symptom scores, patient utilities (EQ5D5L), self-management characteristics(HeiQ) and exacerbation frequency.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)